NOVEL MEGAKARYOCYTE REAGENTS

描述：(改编自申请者摘要)本项目的目标是 开发临床级巨核细胞增殖和无血清试剂 差异化。这将使新的造血救援技术成为可能 疾病，如血小板减少症。初步数据表明， 研究人员的无血清培养液中的CD34+细胞目前表现更好 可用的替代方案。建议的试剂将在以下方面进行优化 细胞因子、培养时间等参数。除了临床 应用，该试剂将使体外实验方案标准化 在实验室里。 建议的商业应用：开发一种临床级无血清培养液 这将支持巨核细胞/血小板的增殖/分化 再给病人输血。这种技术在抗击疾病方面将是无价的。 感染和凝血。

Description: (Adapted from Applicant's Abstract) The goal of this project is to develop clinical grade serum-free reagents for megakaryocyte proliferation and differentiation. This will permit novel hematopoietic rescue techniques for disorders such as thrombocytopenias. Preliminary data indicate that culture of CD34+ cells in the investigators' serum-free medium outperformed currently available alternatives. The proposed reagents will be optimized with regard to cytokines, culture times and other parameters. In addition to clinical applications, the reagents will enable the standardization of ex vivo protocols in laboratories. PROPOSED COMMERCIAL APPLICATION: Develop a clinical grade serum-free medium that will support the proliferation/differentiation of megakaryocytes/platelets for reinfusion into patients. Such a technology will be invaluable in fighting diseases/ infections and in coagulation.